Pharmaceuticals company Cipla announced Q3FY26 results Revenue: Rs 7,074 crore against Rs 7,073 crore during Q3FY25, change 0%. EBITDA: Rs 1,255 crore against Rs 1,989 crore during Q3FY25, change -37%. EBITDA Margin: 17.7% for Q3FY26. PAT: Rs 676 crore against Rs 1571 crore during Q3FY25, change -57%. Umang Vohra, MD & Global CEO, Cipla & Achin Gupta, MD & Global CEO (Designate), Cipla, said: “We are pleased to share that we continue to make considerable progress across our focused markets. In Q3FY26, we delivered global revenues of Rs 7,074 crore, despite the known drop in gRevlimid sales. Our OneIndia business grew at solid 10% YoY. Branded Prescription business delivered a double-digit growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of USD 167 million during the quarter. Our upcoming launches are expected to cushion gRevlimid revenue decline and provide long-term growth. Our South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 7% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.” Result PDF